Bio-Techne's Biotech Surprise: Funding Has Boosted, But Spending Hasn't — A Timing Mismatch

A Surprise in the End Market

The quarter was a mix of encouraging stabilization and an unwelcome step-down in the most anticipated end market. Bio-Techne reported Q3 FY26 revenue of $311M, down 2% organically, but after excluding the 400bps headwind from two Fast Track cell therapy customers and an OEM order timing shift, underlying growth was +2%. That underlying performance was supported by sustained large pharma growth (low double digits, sixth consecutive quarter) and the first return to growth in U.S. academia in several quarters.

But the CEO, Kim Kelderman, was candid about the disappointment: “the biotech end market was indeed our surprise.” — Kim Kelderman, President and Chief Executive Officer · 2026-05-06 Emerging biotech revenue declined high single digits, a deterioration from the mid-single-digit decline last quarter, and the opposite of the stabilization the company had expected given the strong funding data (up >90% in the December quarter and ~50% in March). The company now attributes the step-down to a funding mix shift: emerging biotechs (early-stage) saw actual funding decline, while later-stage biotech absorbed the increased capital. So the core reagent portfolio, which reads directly on early-stage discovery, remained soft.

Jim Hippel, CFO, explained the pacing:

It's like trying to thread a needle here with regards to exactly what quarter you see the inflection point... the average or the mean is somewhere between 2 and 3 quarters. And the reality is it's only been 2 quarters of solid funding. So we're kind of right at that median point now.

Underlying Strength and Platforms

Despite the biotech drag, the company's growth vectors are outperforming. Spatial biology grew mid-teens, with COMET up >65% and a record backlog. GMP proteins ex the two Fast Track customers grew nearly 50%. China posted a fourth consecutive quarter of growth, and the company continues to see momentum in its Bio-Techne Spatial Biology portfolio. Proteomic analysis (Ella, Maurice) also delivered mid-single-digit growth, aided by the recent CE-IVD marking for Ella. These are the platforms that should benefit first when biotech funding converts, as Hippel indicated earlier in the call.

The company also reiterated its commitment to U.S. academic stabilization, which historically leads instrument and spatial ordering. And while cell therapy customers (the two Fast Track accounts) remain a headwind through Q4, the underlying funnel (700+ customers, 85 clinical programs) is building, and management expects the headwind to fully roll off by FY27.

Guidance and the Path to FY27

For Q4, the company guides to roughly flat organic growth, with a 150bps cell therapy headwind, and assumes no further deterioration in biotech. This is more conservative than the mid-single-digit Q4 growth implied last quarter when the company said: “We haven't come off our low single-digit view for the full year. And that would require mid-single-digit growth in Q4 at least.” — James T. Hippel, Chief Financial Officer · 2026-02-04 That shift signals the company is pushing the recovery out, but it also maintains its confidence in FY27: “we're very encouraged about the upcoming fiscal year. Some of these headwinds that are company-specific will now finally be behind us.” — James Hippel, Chief Financial Officer · 2026-05-06

Prior guidance from the February call also reinforced the underlying strength: “If you take these two large customers from the GMP headwinds out, would that be the underlying growth? And I think that's in the ballpark.” — Kim Kelderman, President and Chief Executive Officer · 2026-02-04 The company has consistently highlighted that excluding the Fast Track accounts, the business grows low-to-mid single digits, and that the COMET Multiomic Spatial platform is a share-gainer.

GAAP operating margin improved to 24.2% in Q3, reflecting disciplined expense management and productivity, even as revenue declined. Adjusted operating margin came in at 34.2%, up 310bp sequentially, and the company reiterated ~100bp expansion for the year. With near-zero net debt (<$1x EBITDA) and $210M cash, the balance sheet remains a strategic asset for M&A, which management continues to prioritize.

The stock has rallied ~30% over the past 90 days, suggesting the market is already pricing in the FY27 recovery. The key question is whether the biotech lag converts as management expects. For now, the company's positioning—Spatial, cell therapy, proteomic analysis, and China—offers multiple engines to return to mid-single-digit growth once the biotech funding flows through, making FY27 the pivotal year.